Journal of Clinical Lipidology
Volume 1, Issue 6 , Pages 605-613 , December 2007

Efficacy of controlled-release niacin in treatment of metabolic syndrome: Correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation

  • Christopher S. Vaccari, MD

      Affiliations

    • Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital/Vascular Research Laboratory, 69 Jesse Hill Drive SE #C247, Atlanta, GA 30303, USA
    • ,
  • Sameer Nagamia, MD

      Affiliations

    • Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital/Vascular Research Laboratory, 69 Jesse Hill Drive SE #C247, Atlanta, GA 30303, USA
    • ,
  • Martin Thoenes, MD

      Affiliations

    • Institut fur Klinische Pharmakologie, Technical University, Dresden, Germany
    • ,
  • Asahiko Oguchi, MD

      Affiliations

    • Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital/Vascular Research Laboratory, 69 Jesse Hill Drive SE #C247, Atlanta, GA 30303, USA
    • ,
  • Ramadan Hammoud, MD

      Affiliations

    • Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital/Vascular Research Laboratory, 69 Jesse Hill Drive SE #C247, Atlanta, GA 30303, USA
    • ,
  • Bobby V. Khan, MD, PhD

      Affiliations

    • Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital/Vascular Research Laboratory, 69 Jesse Hill Drive SE #C247, Atlanta, GA 30303, USA

References 

  1. Reaven GM. Banting lecture 1988 (Role of insulin resistance in human disease). Diabetes. 1988;37:1595–1607
  2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403–414
  3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428
  4. Han SH, Quon MJ, Kim J-A, Koh KK. Adiponectin and cardiovascular disease. J Am Coll Cardiol. 2007;49:531–538
  5. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031–H2041
  6. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism. 2004;53:589–593
  7. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–228
  8. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes. 2004;53:2473–2478
  9. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18 year follow-up of a large cohort from Southern Germany. J Am Coll Cardiol. 2006;48:1369–1377
  10. Salmenniemi U, Ruotsalainen E, Pihlajamaki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110:3842–3848
  11. Kumada M, Kihara S, Sumitsuji S, et al. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89
  12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  13. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  14. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  15. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2007;193:361–365
  16. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  17. Kuvin JT, Dave DM, Sliney KA. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743–745
  18. Kuvin JT, Ramet ME, Patel RA, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144:165–172
  19. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254–257
  20. Thoenes M, Oguchi A, Vaccari C, et al. The effects of extended release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with metabolic syndrome. Int J Clin Pract. In press.
  21. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial (ADVENT). Arch Intern Med. 2002;162:1568–1576
  22. Khan BV, Sola S, Lauten WB, et al. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004;27:1712–1715
  23. Allison MA, Tiefenbrun J, Langer RD, Wright CM. Atherosclerotic calcification and intimal medial thickness of the carotid arteries. Int J Cardiol. 2005;103:98–104
  24. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol. 2002;39:257–265
  25. Al Shaer MH, Jerome WP. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 Study. Am J Cardiol. 2006;98:275–276
  26. Brown BG. Niaspan® in the management of dyslipidemia: the evidence. Eur Heart J Suppl. 2006;8(suppl F):F60–F67

 Corresponding author.

PII: S1933-2874(07)00284-X

doi: 10.1016/j.jacl.2007.10.002

Journal of Clinical Lipidology
Volume 1, Issue 6 , Pages 605-613 , December 2007

Article Tools

* Image Usage & Resolution